Company / Cash & Equivalents
BioRestorative Therapies, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.5M
FY2025
5-year range
$547.9K / $21.0M
FY2021-FY2025
Trend
+175.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $2M.
Based on SEC 10-K filings.
$2M in FY2025 with a 3-year CAGR of -4.1%.
Improved from $884,377 to $2M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -4.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -4.1%, indicating a declining trend.
- In FY2025, cash & equivalents increased 175.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5M | +175.8% |
| FY2024 | $547.9K | -38.0% |
| FY2023 | $884.4K | -48.4% |
| FY2022 | $1.7M | -91.8% |
| FY2021 | $21.0M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026